Kestra Advisory Services LLC bought a new stake in shares of Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 12,500 shares of the company’s stock, valued at approximately $64,000.
Separately, 683 Capital Management LLC purchased a new stake in Candel Therapeutics during the 4th quarter valued at about $320,000. Institutional investors and hedge funds own 24.23% of the company’s stock.
Wall Street Analyst Weigh In
Separately, BMO Capital Markets dropped their target price on Candel Therapeutics from $18.00 to $12.00 and set an “outperform” rating for the company in a report on Thursday, March 31st.
Candel Therapeutics Trading Up 4.3 %
Candel Therapeutics (NASDAQ:CADL – Get Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.46. Candel Therapeutics had a negative return on equity of 29.17% and a negative net margin of 29,132.26%. Analysts predict that Candel Therapeutics, Inc. will post -1.92 EPS for the current year.
Candel Therapeutics Profile
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- Can These Two Airline Stocks Overcome Gravity And Fly Higher?
- Shopify Stock Rallies Despite Quarterly Loss
- Two Automation Stocks The Institutions Are Buying
- Can Owens-Corning Insulate Your Portfolio?
- Consumer Staple Kraft-Heinz Quietly Builds Momentum
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.